Pharmacist-led DE-eSCALation of opioids post-surgical dischargE (DESCALE) - A multi-centre, non-randomised, feasibility study protocol.

NIHR open research Pub Date : 2025-04-10 eCollection Date: 2024-01-01 DOI:10.3310/nihropenres.13716.2
Emma L Veale, Johanna Theron, Melanie Rees-Roberts, Julie H Hedayioglu, Ellie Santer, Sabina Hulbert, Vanessa J Short
{"title":"Pharmacist-led DE-eSCALation of opioids post-surgical dischargE (DESCALE) - A multi-centre, non-randomised, feasibility study protocol.","authors":"Emma L Veale, Johanna Theron, Melanie Rees-Roberts, Julie H Hedayioglu, Ellie Santer, Sabina Hulbert, Vanessa J Short","doi":"10.3310/nihropenres.13716.2","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Opioids are frequently prescribed for short-term acute pain following surgery. Used appropriately, opioids deliver extremely favourable pain relief. Used longer than 90-days, however, can result in health complications, including unintentional overdose and addiction. Globally, >40 million people are dependent on opioids and annually >100,000 die from opioid misuse. With >4.7 million surgical procedures occurring annually in the United Kingdom it is imperative that opioid-use is managed upon discharge. A declining General Practitioner (GP) workforce and increased patient numbers, however, means gaps in healthcare during transfer of care. Here we report a mixed-methods protocol to understand the feasibility, and acceptability of a clinical pharmacist (CP)-led early opioid deprescribing intervention for discharged surgical patients.</p><p><strong>Methods: </strong>DESCALE is a multicentre, non-randomised, pragmatic feasibility study. Participants aged ≥18 years who have undergone a surgical procedure at a single NHS trust in Southeast England and discharged with opioids and without a history of long-term opioid use, cancer diagnosis or study contraindications will be offered a Medicines Use Review (MUR) within 7-10 days of discharge. The MUR will be delivered by CPs at participating GP practices. Feasibility outcomes will focus on recruitment, fidelity of CPs to deliver the MUR, and barriers within primary care that affect delivery of the intervention, with a maximum sample size of 100. Clinical outcomes will focus on the number of participants that reduce or stop opioid use within 91 days. Prescribing, medical, surgical, and demographic data for individual participants will be collected and analysed to inform future trial design. Qualitative interviews with participants and associated healthcare professionals will explore acceptability and implementation of the intervention.</p><p><strong>Conclusion: </strong>Data collected with respect to opioid use post-surgery, feasibility and acceptability of the intervention, patient experience and outcome data will inform the design of future research and larger clinical trials.</p>","PeriodicalId":74312,"journal":{"name":"NIHR open research","volume":"4 ","pages":"48"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11757927/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NIHR open research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3310/nihropenres.13716.2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Opioids are frequently prescribed for short-term acute pain following surgery. Used appropriately, opioids deliver extremely favourable pain relief. Used longer than 90-days, however, can result in health complications, including unintentional overdose and addiction. Globally, >40 million people are dependent on opioids and annually >100,000 die from opioid misuse. With >4.7 million surgical procedures occurring annually in the United Kingdom it is imperative that opioid-use is managed upon discharge. A declining General Practitioner (GP) workforce and increased patient numbers, however, means gaps in healthcare during transfer of care. Here we report a mixed-methods protocol to understand the feasibility, and acceptability of a clinical pharmacist (CP)-led early opioid deprescribing intervention for discharged surgical patients.

Methods: DESCALE is a multicentre, non-randomised, pragmatic feasibility study. Participants aged ≥18 years who have undergone a surgical procedure at a single NHS trust in Southeast England and discharged with opioids and without a history of long-term opioid use, cancer diagnosis or study contraindications will be offered a Medicines Use Review (MUR) within 7-10 days of discharge. The MUR will be delivered by CPs at participating GP practices. Feasibility outcomes will focus on recruitment, fidelity of CPs to deliver the MUR, and barriers within primary care that affect delivery of the intervention, with a maximum sample size of 100. Clinical outcomes will focus on the number of participants that reduce or stop opioid use within 91 days. Prescribing, medical, surgical, and demographic data for individual participants will be collected and analysed to inform future trial design. Qualitative interviews with participants and associated healthcare professionals will explore acceptability and implementation of the intervention.

Conclusion: Data collected with respect to opioid use post-surgery, feasibility and acceptability of the intervention, patient experience and outcome data will inform the design of future research and larger clinical trials.

以药剂师为主导的手术后阿片类药物减量(DESCALE)--一项多中心、非随机、可行性研究方案。
背景:阿片类药物常用于手术后短期急性疼痛。使用得当,阿片类药物提供非常有利的疼痛缓解。然而,使用超过90天,可能会导致健康并发症,包括意外过量和成瘾。全球有4000万人依赖阿片类药物,每年有10万人死于阿片类药物滥用。英国每年有470万例外科手术,必须在出院时对阿片类药物的使用进行管理。然而,全科医生(GP)劳动力的减少和患者数量的增加意味着在护理转移期间的医疗保健差距。在这里,我们报告了一种混合方法的方案,以了解临床药剂师(CP)主导的早期阿片类药物处方干预出院手术患者的可行性和可接受性。方法:DESCALE是一项多中心、非随机、实用的可行性研究。年龄≥18岁、在英格兰东南部单一NHS信托机构接受过外科手术、出院时使用阿片类药物且无长期阿片类药物使用史、癌症诊断或研究禁忌症的参与者将在出院后7-10天内接受药物使用审查(MUR)。murr将由参与全科医生实践的CPs提供。可行性结果将侧重于招募、cp提供最低死亡率的忠实度,以及初级保健中影响干预措施提供的障碍,最大样本量为100。临床结果将集中在91天内减少或停止使用阿片类药物的参与者数量。将收集和分析个体参与者的处方、医学、外科和人口统计数据,为未来的试验设计提供信息。与参与者和相关医疗保健专业人员的定性访谈将探讨干预措施的可接受性和实施。结论:收集的有关术后阿片类药物使用、干预的可行性和可接受性、患者体验和结果数据将为未来研究和更大规模临床试验的设计提供信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信